Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...

PTC Therapeutics, Inc. today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company's ...

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

From respiratory infection to fatal neurological disease, EHV-1 demands rapid PCR diagnosis, and detection protocols impact ...

Most of the original Israeli investors - mainly OrbiMed and Pontifax Venture Capital - exited around the IPO, and as far as ...

The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.

This year marked a pivotal moment in the quest to treat Huntington’s disease, a rare but devastating form of dementia. Scientists found that an experimental gene therapy slowed the condition’s ...

Families with Huntington’s need this to be true more than most. The devastating neurodegenerative disease is caused by a CAG ...

UCI’s $12M CIRM award for hNSC-01 marks a pivotal shift to clinical-stage development. See how this state-funded "bridge" is de-risking regenerative medicine for Huntington’s.

Qure N.V. (NASDAQ:QURE) surged around 15% in early trading on Friday after the company said it has secured a Type A meeting ...

Scientist John Cleary points to a screen on the Xenium Analyzer in the Next Generation Transcriptomic Facility at the University at Albany on Tuesday in Albany. Around 50 to 70 diseases are believed ...